Ovarian Cancer

The evaluation of noncytotoxic agents for the treatment of epithelial ovarian cancer has produced encouraging findings in recent months, which has led to the approval of new agents with novel mechanisms of action and continuing studies into many more potential therapies.

Sanaz Memarzadeh, MD, PhD, gynecologic oncology, obstetrics and gynecology, University of California, Los Angeles, discusses recurrence rates in ovarian cancer.

The jury is still out on whether use of an algorithm to help classify risk levels in ovarian cancer can improve overall survival but a company is already marketing the system in Britain and plans to bring it to the United States before the end of the year.

Nivolumab (Opdivo) demonstrated clinical activity and safety in patients with platinum-resistant ovarian cancer.

Sanaz Memarzadeh, MD, PhD, discusses a combination regimen of birinapant and carboplatin in patients with high-grade serous ovarian cancers and high levels of cellular inhibitor of apoptosis protein (cIAP) in their CA-125–negative cells.

Robert L. Coleman, MD, The University of Texas MD Anderson Cancer Center, discusses the next steps following results of the ARIEL2 trial, which aimed to identify patients with ovarian cancer most likely to respond to rucaparib using tumor genetic analysis.

Research evidence has been mounting that PARP inhibitors are not just for gynecologic malignancies-or for patients whose tumors harbor inherited BRCA defects.

Noah D. Kauff, MD, FACOG, gynecologist and geneticist, director, Ovarian Cancer Screening and Prevention, Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses the main challenges in treating uterine cancer.

Jeffrey R. Infante, MD, discusses the fully human PD-L1 IgG1 antibody avelumab, which demonstrated clinical activity in patients with previously treated, recurrent/refractory ovarian cancer in a phase Ib open-label expansion trial.

Frontline treatment with intraperitoneal chemotherapy is commonly underutilized for a majority of patients with optimally cytoreduced stage III ovarian cancer, despite recommendations for its use and a clear demonstration of improved overall survival.

Premal H. Thaker, MD, discusses EGEN-001 in combination with pegylated liposomal doxorubicin and the potential of immunotherapy agents in ovarian and other similar cancers.

Premal H. Thaker, MD, MS, discusses a phase I study examining the combination of EGEN-001 and doxorubicin for the treatment of patients with platinum-resistant ovarian cancer.

Women with ovarian cancer who experienced an average dose reduction of ≤85% had a 35% higher mortality risk than those who received normal dosing.

Jeffrey R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses the potential impact avelumab could have on the treatment of patients with ovarian cancer.

Robert Coleman, MD, discusses a potential new biomarker for PARP inhibition in ovarian cancer that was examined in the ARIEL2 trial.

The FDA has granted an orphan drug designation to the immunotherapy DPX-Survivac as a treatment for women with ovarian cancer.